{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:50:46Z","timestamp":1794466246331,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55770-1","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T12:31:37Z","timestamp":1736944297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3082-1291","authenticated-orcid":false,"given":"Stefano","family":"Pierini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Gabbasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-3918","authenticated-orcid":false,"given":"Maria Cecilia","family":"Oliveira-Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehman","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8769-1129","authenticated-orcid":false,"given":"Alison","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurong","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Yashiro-Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleigh","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sloas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4553-4068","authenticated-orcid":false,"given":"Benjamin","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Sonawane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linara","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotheavy","family":"Chhum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Minutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Ciccaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Zentner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyam","family":"Levitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Shestova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7778","authenticated-orcid":false,"given":"Saar","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cushing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Ceeraz DeLong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9450-2762","authenticated-orcid":false,"given":"Thomas","family":"Condamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-163X","authenticated-orcid":false,"given":"Michael","family":"Klichinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"55770_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"55770_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41470-9","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nat. Commun. 14, 5778 (2023).","journal-title":"Nat. Commun."},{"key":"55770_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102\u2013116 (2024).","journal-title":"Nat. Immunol."},{"key":"55770_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"55770_CR5","doi-asserted-by":"crossref","unstructured":"Morrissey, M. A. et al. Chimeric antigen receptors that trigger phagocytosis. Elife 7 (2018).","DOI":"10.7554\/eLife.36688"},{"key":"55770_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41590-023-01696-7","volume":"25","author":"SM Abdin","year":"2024","unstructured":"Abdin, S. M., Paasch, D. & Lachmann, N. CAR macrophages on a fast track to solid tumor therapy. Nat. Immunol. 25, 11\u201312 (2024).","journal-title":"Nat. Immunol."},{"key":"55770_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103873","volume":"76","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. CAR-macrophage: an extensive immune enhancer to fight cancer. EBioMedicine 76, 103873 (2022).","journal-title":"EBioMedicine"},{"key":"55770_CR8","first-page":"A1739","volume":"11","author":"B Varghese","year":"2023","unstructured":"Varghese, B. et al. 1514 In vivo CAR-M: redirecting endogenous myeloid cells with mRNA for cancer immunotherapy. J. Immunother. Cancer 11, A1739\u2013A1739 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"55770_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257\u2013265 (2015).","journal-title":"Lancet Oncol."},{"key":"55770_CR10","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"55770_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.724424","volume":"11","author":"F Chen","year":"2021","unstructured":"Chen, F. et al. Clinical progress of PD-1\/L1 inhibitors in breast cancer immunotherapy. Front. Oncol. 11, 724424 (2021).","journal-title":"Front. Oncol."},{"key":"55770_CR12","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2147\/OTT.S186271","volume":"12","author":"Z Fan","year":"2019","unstructured":"Fan, Z. et al. A meta-analysis of the efficacy and safety of PD-1\/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer. Onco Targets Ther. 12, 1791\u20131801 (2019).","journal-title":"Onco Targets Ther."},{"key":"55770_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","volume":"34","author":"DF McDermott","year":"2016","unstructured":"McDermott, D. F. et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J. Clin. Oncol. 34, 833\u2013842 (2016).","journal-title":"J. Clin. Oncol."},{"key":"55770_CR14","doi-asserted-by":"crossref","unstructured":"Mayoux, M. et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci. Transl. Med. 12 (2020).","DOI":"10.1126\/scitranslmed.aav7431"},{"key":"55770_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110331","volume":"38","author":"J Nagasaki","year":"2022","unstructured":"Nagasaki, J. et al. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. Cell Rep. 38, 110331 (2022).","journal-title":"Cell Rep."},{"key":"55770_CR16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen, A. et al. Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389\u20131399 (2023).","journal-title":"Nat. Med."},{"key":"55770_CR17","doi-asserted-by":"crossref","unstructured":"Balanca, C. C. et al. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight 6 (2021).","DOI":"10.1172\/jci.insight.142513"},{"key":"55770_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"55770_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","volume":"23","author":"S Goswami","year":"2023","unstructured":"Goswami, S., Anandhan, S., Raychaudhuri, D. & Sharma, P. Myeloid cell-targeted therapies for solid tumours. Nat. Rev. Immunol. 23, 106\u2013120 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"55770_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","journal-title":"Nat. Commun."},{"key":"55770_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","volume":"24","author":"TS Nowicki","year":"2018","unstructured":"Nowicki, T. S., Hu-Lieskovan, S. & Ribas, A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 24, 47\u201353 (2018).","journal-title":"Cancer J."},{"key":"55770_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","volume":"20","author":"S Loi","year":"2019","unstructured":"Loi, S. et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 20, 371\u2013382 (2019).","journal-title":"Lancet Oncol."},{"key":"55770_CR23","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo, N. et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N. Engl. J. Med. 385, 1856\u20131867 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55770_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden, M. R. et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl. J. Med. 379, 341\u2013351 (2018).","journal-title":"N. Engl. J. Med."},{"key":"55770_CR25","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem, P. T. et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N. Engl. J. Med 374, 2542\u20132552 (2016).","journal-title":"N. Engl. J. Med"},{"key":"55770_CR26","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian, Y. Y. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 402, 2197\u20132208 (2023).","journal-title":"Lancet"},{"key":"55770_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727\u2013730 (2021).","journal-title":"Nature"},{"key":"55770_CR28","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens, L. A. et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 21, 1283\u20131295 (2020).","journal-title":"Lancet Oncol."},{"key":"55770_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1128\/JVI.01265-10","volume":"85","author":"AU Barlan","year":"2011","unstructured":"Barlan, A. U., Griffin, T. M., McGuire, K. A. & Wiethoff, C. M. Adenovirus membrane penetration activates the NLRP3 inflammasome. J. Virol. 85, 146\u2013155 (2011).","journal-title":"J. Virol."},{"key":"55770_CR30","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1128\/JVI.02702-13","volume":"88","author":"E Lam","year":"2014","unstructured":"Lam, E., Stein, S. & Falck-Pedersen, E. Adenovirus detection by the cGAS\/STING\/TBK1 DNA sensing cascade. J. Virol. 88, 974\u2013981 (2014).","journal-title":"J. Virol."},{"key":"55770_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/cr.2015.68","volume":"25","author":"B Kelly","year":"2015","unstructured":"Kelly, B. & O\u2019Neill, L. A. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res 25, 771\u2013784 (2015).","journal-title":"Cell Res"},{"key":"55770_CR32","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.4049\/jimmunol.178.8.5245","volume":"178","author":"AJ Fleetwood","year":"2007","unstructured":"Fleetwood, A. J., Lawrence, T., Hamilton, J. A. & Cook, A. D. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J. Immunol. 178, 5245\u20135252 (2007).","journal-title":"J. Immunol."},{"key":"55770_CR33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792\u2013809.e723 (2021).","journal-title":"Cell"},{"key":"55770_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/01.cji.0000436722.46675.4a","volume":"36","author":"MG Lechner","year":"2013","unstructured":"Lechner, M. G. et al. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J. Immunother. 36, 477\u2013489 (2013).","journal-title":"J. Immunother."},{"key":"55770_CR35","doi-asserted-by":"crossref","unstructured":"Fabian, K. P., Padget, M. R., Fujii, R., Schlom, J. & Hodge, J. W. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. J. Immunother. Cancer 9 (2021).","DOI":"10.1136\/jitc-2020-001691"},{"key":"55770_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/cmi.2014.130","volume":"12","author":"Y Liu","year":"2015","unstructured":"Liu, Y. & Cao, X. Intratumoral dendritic cells in the anti-tumor immune response. Cell Mol. Immunol. 12, 387\u2013390 (2015).","journal-title":"Cell Mol. Immunol."},{"key":"55770_CR37","doi-asserted-by":"publisher","first-page":"26771","DOI":"10.18632\/oncotarget.15816","volume":"8","author":"S Nilofar Danishmalik","year":"2017","unstructured":"Nilofar Danishmalik, S., Lee, S. H. & Sin, J. I. Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2\/HER2 tumor model: no involvement of CD80 in tumor control. Oncotarget 8, 26771\u201326788 (2017).","journal-title":"Oncotarget"},{"key":"55770_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1181014","volume":"14","author":"Z Taha","year":"2023","unstructured":"Taha, Z. et al. Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus. Front. Immunol. 14, 1181014 (2023).","journal-title":"Front. Immunol."},{"key":"55770_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez, M., Moon, E. K. & CAR, T. Cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019).","journal-title":"Front. Immunol."},{"key":"55770_CR40","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson, N. R., Minutolo, N. G., Gill, S. & Klichinsky, M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81, 1201\u20131208 (2021).","journal-title":"Cancer Res."},{"key":"55770_CR41","doi-asserted-by":"crossref","unstructured":"Lhuillier, C. et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J. Clin. Invest. 131 (2021).","DOI":"10.1172\/JCI138740"},{"key":"55770_CR42","doi-asserted-by":"crossref","unstructured":"Nahar, S. et al. Regression and eradication of triple-negative breast carcinoma in 4T1 mouse model by combination immunotherapies. Cancers (Basel) 15 (2023).","DOI":"10.3390\/cancers15082366"},{"key":"55770_CR43","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41418-020-00658-y","volume":"28","author":"TL Aaes","year":"2021","unstructured":"Aaes, T. L. & Vandenabeele, P. The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses. Cell Death Differ. 28, 843\u2013860 (2021).","journal-title":"Cell Death Differ."},{"key":"55770_CR44","doi-asserted-by":"crossref","unstructured":"Kim, A. B. et al. Chimeric antigen receptor macrophages target and resorb amyloid plaques. JCI Insight 9 (2024).","DOI":"10.1172\/jci.insight.175015"},{"key":"55770_CR45","doi-asserted-by":"publisher","first-page":"741305","DOI":"10.3389\/fimmu.2021.741305","volume":"12","author":"Z He","year":"2021","unstructured":"He, Z. & Zhang, S. Tumor-associated macrophages and their functional transformation in the hypoxic tumor microenvironment. Front. Immunol. 12, 741305 (2021).","journal-title":"Front. Immunol."},{"key":"55770_CR46","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei, Q., Wang, D., Sun, K., Wang, L. & Zhang, Y. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front Cell Dev. Biol. 8, 672 (2020).","journal-title":"Front Cell Dev. Biol."},{"key":"55770_CR47","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu, Y. et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057\u20135069 (2014).","journal-title":"Cancer Res."},{"key":"55770_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nri.2017.28","volume":"17","author":"CV Jakubzick","year":"2017","unstructured":"Jakubzick, C. V., Randolph, G. J. & Henson, P. M. Monocyte differentiation and antigen-presenting functions. Nat. Rev. Immunol. 17, 349\u2013362 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"55770_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale, I., Manic, G., Coussens, L. M., Kroemer, G. & Galluzzi, L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36\u201350 (2019).","journal-title":"Cell Metab."},{"key":"55770_CR50","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc.2016.54","volume":"16","author":"C Engblom","year":"2016","unstructured":"Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447\u2013462 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"55770_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49\u201361 (2014).","journal-title":"Immunity"},{"key":"55770_CR52","doi-asserted-by":"publisher","first-page":"9730","DOI":"10.1073\/pnas.93.18.9730","volume":"93","author":"AY Huang","year":"1996","unstructured":"Huang, A. Y. et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl Acad. Sci. USA 93, 9730\u20139735 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55770_CR53","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.vaccine.2008.01.052","volume":"26","author":"JA McWilliams","year":"2008","unstructured":"McWilliams, J. A. et al. Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine 26, 1863\u20131873 (2008).","journal-title":"Vaccine"},{"key":"55770_CR54","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187\u20132194 (2010).","journal-title":"J. Exp. Med."},{"key":"55770_CR55","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch, L. et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350\u20132360 (2011).","journal-title":"J. Clin. Invest."},{"key":"55770_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"55770_CR57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","volume":"41","author":"N Porciello","year":"2022","unstructured":"Porciello, N., Franzese, O., D\u2019Ambrosio, L., Palermo, B. & Nistico, P. T-cell repertoire diversity: friend or foe for protective antitumor response? J. Exp. Clin. Cancer Res. 41, 356 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"55770_CR58","first-page":"A726","volume":"11","author":"K Reiss","year":"2023","unstructured":"Reiss, K. et al. 635A phase 1, first in human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors. J. Immunother. Cancer 11, A726\u2013A726 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"55770_CR59","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/1538-7445.AM2022-582","volume":"82","author":"D Blumenthal","year":"2022","unstructured":"Blumenthal, D. et al. Abstract 582: pre-clinical development of CAR Monocytes (CAR Mono) for solid tumor immunotherapy. Cancer Res. 82, 582\u2013582 (2022).","journal-title":"Cancer Res."},{"key":"55770_CR60","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature01392","volume":"421","author":"HS Cho","year":"2003","unstructured":"Cho, H. S. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756\u2013760 (2003).","journal-title":"Nature"},{"key":"55770_CR61","first-page":"319","volume":"49","author":"MH Ullman-Cullere","year":"1999","unstructured":"Ullman-Cullere, M. H. & Foltz, C. J. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim. Sci. 49, 319\u2013323 (1999).","journal-title":"Lab Anim. Sci."},{"key":"55770_CR62","first-page":"14 11 11","volume":"Chapter 14","author":"X Zhang","year":"2008","unstructured":"Zhang, X., Goncalves, R. & Mosser, D. M. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. Chapter 14, 14 11 11\u201314 11 14 (2008).","journal-title":"Curr. Protoc. Immunol."},{"key":"55770_CR63","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.4049\/jimmunol.1500281","volume":"195","author":"S Pierini","year":"2015","unstructured":"Pierini, S. et al. A tumor mitochondria vaccine protects against experimental renal cell carcinoma. J. Immunol. 195, 4020\u20134027 (2015).","journal-title":"J. Immunol."},{"key":"55770_CR64","doi-asserted-by":"crossref","unstructured":"Pierini, S. et al. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression. J. Immunother. Cancer 9 (2021).","DOI":"10.1136\/jitc-2020-001636"},{"key":"55770_CR65","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins, H. S. et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099\u20134107 (2009).","journal-title":"Blood"},{"key":"55770_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3680","volume":"4","author":"CS Carlson","year":"2013","unstructured":"Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).","journal-title":"Nat. Commun."},{"key":"55770_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jim.2011.09.001","volume":"375","author":"H Robins","year":"2012","unstructured":"Robins, H. et al. Ultra-sensitive detection of rare T cell clones. J. Immunol. Methods 375, 14\u201319 (2012).","journal-title":"J. Immunol. Methods"},{"key":"55770_CR68","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1128\/JVI.03474-14","volume":"89","author":"WS DeWitt","year":"2015","unstructured":"DeWitt, W. S. et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J. Virol. 89, 4517\u20134526 (2015).","journal-title":"J. Virol."},{"key":"55770_CR69","doi-asserted-by":"crossref","unstructured":"Simpson, E. Measurement of diversity. Nature 163 (1949).","DOI":"10.1038\/163688a0"},{"key":"55770_CR70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"55770_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"55770_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).","journal-title":"Genome Biol."},{"key":"55770_CR73","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"55770_CR74","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/ni1008-1091","volume":"9","author":"TS Heng","year":"2008","unstructured":"Heng, T. S., Painter, M. W. & Immunological Genome Project, C. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091\u20131094 (2008).","journal-title":"Nat. Immunol."},{"key":"55770_CR75","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.immuni.2015.05.018","volume":"42","author":"J Helft","year":"2015","unstructured":"Helft, J. et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity 42, 1197\u20131211 (2015).","journal-title":"Immunity"},{"key":"55770_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."}],"updated-by":[{"DOI":"10.1038\/s41467-025-57496-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55770-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55770-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55770-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T14:45:35Z","timestamp":1742481935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55770-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55770"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55770-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-025-57496-0","URL":"https:\/\/doi.org\/10.1038\/s41467-025-57496-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K. and S.G. are scientific co-founders of Carisma Therapeutics Inc, equity shareholders, and inventors of patents related to this work. S.P., R.G., M.C.O.-N., R.Q., A.W., S.H., K.N., C.G., L.L., Y.O., K.R., C.S., M.B., B.S., P.S., L.C., D.B., S.C., N.M., K.C., L.S., I.Z., D.C., S.C.D, S.A., T.C., and M.K. are employees of Carisma Therapeutics Inc and equity shareholders. H.L and S.G. are Scientific Advisory Board Members and shareholders of Carisma Therapeutics Inc. S.G. has patents related to CAR therapy with royalties paid from Novartis to the University of Pennsylvania. S.G. is a scientific co-founder and holds equity in Interius Biotherapeutics and Carisma Therapeutics Inc. S.G. is a scientific advisor to Carisma, Cartography, Currus, Interius, Kite, NKILT, Mission Bio, and Vor Bio. O.S. declares no competing interests. This work was funded by Carisma Therapeutics Inc which is pursuing the commercial development of related products.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"706"}}